Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.
McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK.
McLaughlin P, et al. Among authors: wey k.
J Clin Oncol. 2023 Jan 10;41(2):154-162. doi: 10.1200/JCO.22.02403.
J Clin Oncol. 2023.
PMID: 36603541
Clinical Trial.